Login / Signup

Complicated regulatory decision-making following inconsistent trial results: the issue with ibrutinib for mantle cell lymphoma.

Edward Robert Scheffer CliffTalal HilalAaron S Kesselheim
Published in: Nature reviews. Clinical oncology (2023)
Keyphrases
  • decision making
  • phase iii
  • study protocol
  • phase ii
  • clinical trial
  • transcription factor
  • chronic lymphocytic leukemia
  • randomized controlled trial
  • open label